Wandercraft is a French robotics firm based in 2012 by Nicolas Simon, Matthieu Masselin, and Jean-Louis Constanza. The founders had been motivated by private experiences, as relations suffered from Charcot Marie Tooth, or CMT, illness and confronted restricted mobility choices.
The firm‘s main objective till now has been to allow folks with extreme gait and mobility impairments to face and stroll once more. Wandercraft developed a product line of dependable, self-balancing exoskeletons able to safely carrying an individual.
Renault to assist develop industrial robotics
This week, Wandercraft unveiled its first humanoid robotic referred to as Calvin. The corporate claimed that it developed the robotic in 40 days, utilizing parts of its exoskeleton merchandise.
The brand new mission comes on the heels of an announcement that Renault Group is making a minority funding in Wandercraft. The automaker is investing together with Wandercraft’s present shareholders and new traders.
The business companions mentioned they goal to make sure the event of Calvin as a household of next-generation robots, primarily for industrial makes use of. Calvin will permit Renault to alleviate its employees from painful and non-ergonomic duties, whereas lowering manufacturing time and thereby rising productiveness.
At a later stage, Renault will assist commercialize the robots and exoskeletons by lowering prices via design-to-cost and scaling, two disciplines by which the automotive trade is nicely acknowledged. This can assist Wandercraft to place its new exoskeleton Eve available on the market and open new enterprise alternatives in robotics.
“Renault Group’s funding marks a defining second for Wandercraft,” mentioned Matthieu Masselin, co-founder and CEO. “This partnership will enhance our means to construct and scale high-impact, low-cost robotics that enhance the on a regular basis lives of actual folks—whether or not it’s serving to people with disabilities stroll or supporting industrial employees via automation — on the manufacturing unit flooring, in clinics and at residence. We’re proud to mix our know-how with Renault Group’s industrial excellence to ship the subsequent era of cellular robotics.”
Calvin employs a set of non-grasping arms, and within the video above, the robotic strikes a tote to a shelf. The Robotic Report reached out to the corporate for specs on the robotic, nevertheless it didn’t reply as of press time.
The brand new Calvin humanoid robotic is designed for industrial use. Credit score: Wandercraft
Wandercraft exoskeleton in medical trials
Wandercraft’s main product is the Atalante X, a self-stabilizing exoskeleton designed for rehabilitation settings. Launched in 2019, Atalante X permits sufferers to stroll, stand, and relearn pure human movement from their first session. It’s at the moment utilized in almost 100 rehabilitation and medical analysis facilities worldwide.
Key options embrace ActiveBalance mode and 12 levels of freedom on the hips, knees, and ankles, enabling a pure gait. The Atalante X provides advantages for each sufferers (early rehabilitation, hands-free strolling, excessive step counts, multi-directional motion) and therapists (fast setup, customizable depth, high-intensity coaching, no want for crutches). Atalante X has obtained FDA clearance for people with spinal twine accidents (T5-L5) and stroke sufferers, and it has a CE mark in Europe for numerous circumstances.
The corporate demonstrated the exoskeleton final 12 months when a paraplegic athlete participated in an Olympic flame working occasion.
Following the success of Atalante X, Wandercraft just lately unveiled the Private Exoskeleton, a self-balancing, walk-assist system designed for private, on a regular basis use. The corporate began medical trials of the Private Exoskeleton in February 2025.
This hands-free system goals to offer private freedom of movement in residence and group settings. Like Atalante X, it encompasses a absolutely powered hip-knee-ankle decrease physique with 12 actuated levels of freedom and dynamic strolling management.
The Private Exoskeleton, unveiled as a prototype in December 2023, is in its remaining phases of analysis and growth and can bear medical testing and regulatory assessment earlier than turning into extensively accessible.
Now accepting session submissions!
